Related Experiment Video
Updated: May 26, 2026

Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
Perioperative clotting factor replacement and infection in total knee arthroplasty
J M-L Wong1, H A Mann, N J Goddard
1Specialist Registrar Trauma and Orthopaedics Consultant Orthopaedic Surgeon, The Royal Free Hospital, Pond Street, London, UK. minleong@doctors.org.uk
Abstract:
Total knee arthroplasty, or replacement (TKR), is now the most commonly performed surgical procedure performed in adults with haemophilia. It is indicated when end-stage haemophilic arthropathy results in intractable pain and reduced function. In patients with haemophilia, however, there has always been a concern about the high risk of infection, which carries with it potentially catastrophic consequences. The aims of this study were to review the case series of TKR for haemophilic arthropathy published in the medical literature, comparing the published infection rates and the differing clotting factor replacement regimes employed. Nineteen retrospective case series were identified; representing 556 TKR's in 455 patients with an overall infection rate of 7.9%. Case series which maintained a high level of clotting factor replacement throughout the first two postoperative weeks, however, had an infection rate of 2.15%, significantly lower than that of case series using the clotting factor replacement regime currently recommended in the World Federation of Hemophilia guidelines (9.22% P = 0.00545). We believe this study supports the use of a high level clotting factor replacement regime, replacing clotting factors to maintain them at a higher level for a longer period of time than currently recommended in international guidelines.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management